We report on the data collected in the Italian Registry of acquired haemophilia (AH) in 2001. Recombinant activated factor VII (rFVIIa) was selected as first-line therapy in 19 bleeding episodes because of their severity and as salvage in one case. Bleeding was controlled in 90% of the episodes, indicating the efficacy of rFVIIa in HA.
TREATMENT OF ACQUIRED FACTOR VIII INHIBITOR VIA RECOMBINANT ACTIVATED FACTOR VIIa: DATA FROM THE ITALIAN REGISTRY OF ACQUIRED HEMOPHILIA
GAIDANO, Gianluca
2004-01-01
Abstract
We report on the data collected in the Italian Registry of acquired haemophilia (AH) in 2001. Recombinant activated factor VII (rFVIIa) was selected as first-line therapy in 19 bleeding episodes because of their severity and as salvage in one case. Bleeding was controlled in 90% of the episodes, indicating the efficacy of rFVIIa in HA.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
759.full.pdf
file disponibile solo agli amministratori
Tipologia:
Altro materiale allegato
Licenza:
DRM non definito
Dimensione
251.3 kB
Formato
Adobe PDF
|
251.3 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
